Annexon Inc (ANNX) - Net Assets
Based on the latest financial reports, Annexon Inc (ANNX) has net assets worth $161.44 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($229.14 Million) and total liabilities ($67.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Annexon Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $161.44 Million |
| % of Total Assets | 70.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -14.86% |
| 10-Year Change | N/A |
| Growth Volatility | 257.47 |
Annexon Inc - Net Assets Trend (2017–2024)
This chart illustrates how Annexon Inc's net assets have evolved over time, based on quarterly financial data. Also explore ANNX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Annexon Inc (2017–2024)
The table below shows the annual net assets of Annexon Inc from 2017 to 2024. For live valuation and market cap data, see Annexon Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $293.11 Million | +16.98% |
| 2023-12-31 | $250.56 Million | +8.37% |
| 2022-12-31 | $231.19 Million | -0.31% |
| 2021-12-31 | $231.91 Million | -32.64% |
| 2020-12-31 | $344.28 Million | +690.90% |
| 2019-12-31 | $43.53 Million | +14.92% |
| 2018-12-31 | $37.88 Million | +181.97% |
| 2017-12-31 | $-46.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Annexon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 66360600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $109.00K | 0.04% |
| Other Comprehensive Income | $10.00K | 0.00% |
| Other Components | $1.00 Billion | 342.43% |
| Total Equity | $293.11 Million | 100.00% |
Annexon Inc Competitors by Market Cap
The table below lists competitors of Annexon Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lintes Technology Co Ltd
TW:6715
|
$833.30 Million |
|
Dividend 15 Split Corp
TO:DFN
|
$833.58 Million |
|
Shenzhen SDG Service Co. Ltd.
SHE:300917
|
$833.90 Million |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
$833.96 Million |
|
Vats Liquor Chain Store Management Joint Stock Co Ltd
SHE:300755
|
$833.13 Million |
|
Jinneng Science&Tech Co Ltd
SHG:603113
|
$833.12 Million |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
$833.02 Million |
|
Sana Biotechnology Inc
NASDAQ:SANA
|
$832.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Annexon Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 250,556,000 to 293,105,000, a change of 42,549,000 (17.0%).
- Net loss of 138,200,000 reduced equity.
- New share issuances of 161,871,000 increased equity.
- Other comprehensive income increased equity by 62,000.
- Other factors increased equity by 18,816,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-138.20 Million | -47.15% |
| Share Issuances | $161.87 Million | +55.23% |
| Other Comprehensive Income | $62.00K | +0.02% |
| Other Changes | $18.82 Million | +6.42% |
| Total Change | $- | 16.98% |
Book Value vs Market Value Analysis
This analysis compares Annexon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.70x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.21 | $5.75 | x |
| 2018-12-31 | $3.31 | $5.75 | x |
| 2019-12-31 | $1.14 | $5.75 | x |
| 2020-12-31 | $20.30 | $5.75 | x |
| 2021-12-31 | $6.05 | $5.75 | x |
| 2022-12-31 | $4.23 | $5.75 | x |
| 2023-12-31 | $3.31 | $5.75 | x |
| 2024-12-31 | $2.13 | $5.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Annexon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-47.15%) is below the historical average (-45.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.09 Million |
| 2018 | -48.32% | 0.00% | 0.00x | 1.27x | $-22.09 Million |
| 2019 | -85.42% | 0.00% | 0.00x | 1.15x | $-41.54 Million |
| 2020 | -18.23% | 0.00% | 0.00x | 1.03x | $-97.17 Million |
| 2021 | -55.10% | 0.00% | 0.00x | 1.24x | $-150.98 Million |
| 2022 | -59.82% | 0.00% | 0.00x | 1.23x | $-161.41 Million |
| 2023 | -53.58% | 0.00% | 0.00x | 1.19x | $-159.29 Million |
| 2024 | -47.15% | 0.00% | 0.00x | 1.19x | $-167.51 Million |
Industry Comparison
This section compares Annexon Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Annexon Inc (ANNX) | $161.44 Million | 0.00% | 0.42x | $833.22 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in … Read more